Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Dec 14, 2023 8:53am
247 Views
Post# 35784032

“Within striking distance”

“Within striking distance”

...of enrollment milestone of 90...a potentially major catalyst that could bring with it market attention and millions more in US$ from Baxter 

just nine to go ! !

And they are back to averaging nearly 1 patient per week  into Tigris 
Pace should improve to more than that once final 3-5 sites onboarded , and given recency effect of higher rates of influenza now being reported in US hospitals. 

Eden completed ! Now time to analyze data and have it inform subsequent discussions with the FDA concerning labeling and use of PMX 

Finally last and not least, JK is "highly encouraged by the outlook, given the fact preliminary mortality data continues to exceed our expectations.”

 

Now ...queue the SHOBBS to provide their negative spin on things. 

MM 
<< Previous
Bullboard Posts
Next >>